Notícias argenx SE - ARGX | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
argenx SE (ARGX)
argenx SE (ARGX) Notícias

argenx SE (ARGX)

591,82

17,28

(3,01%)

Fechado 20 Novembro 6:00PM

Atrasado por 15 minutos

579,81

-12,01

( -2,03% )

Pré-mercado: 8:20AM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

argenx to Participate at Upcoming Investor Conferences

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

argenx to Present at Upcoming Investor Conferences

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições